Read more about company updates in our Newsroom where we display all of our Press Releases.
Company Blog Articles
Dr. Robert Hariri, CEO and founder of Celularity, discusses how the company is exploring a new treatment for COVID-19 as the pandemic intensifies.
The FDA cleared an investigational new drug application for CYNK-001 for the treatment of adults with COVID-19 infection, according to the agent’s manufacturer.
Celularity, a New Jersey company developing experimental cancer treatments derived from human placentas, has received the FDA’s blessing to kick off human testing of its lead immunotherapy for cases of COVID-19 disease.